167 related articles for article (PubMed ID: 28930697)
1. Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression.
Lin X; Gu Y; Kapoor A; Wei F; Aziz T; Ojo D; Jiang Y; Bonert M; Shayegan B; Yang H; Al-Nedawi K; Major P; Tang D
Neoplasia; 2017 Nov; 19(11):857-867. PubMed ID: 28930697
[TBL] [Abstract][Full Text] [Related]
2. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of FAM84B during prostate cancer progression.
Wong N; Gu Y; Kapoor A; Lin X; Ojo D; Wei F; Yan J; de Melo J; Major P; Wood G; Aziz T; Cutz JC; Bonert M; Patterson AJ; Tang D
Oncotarget; 2017 Mar; 8(12):19218-19235. PubMed ID: 28186973
[TBL] [Abstract][Full Text] [Related]
4. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
5. Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence.
Jiang Y; Mei W; Gu Y; Lin X; He L; Zeng H; Wei F; Wan X; Yang H; Major P; Tang D
Mol Oncol; 2018 Sep; 12(9):1559-1578. PubMed ID: 30024105
[TBL] [Abstract][Full Text] [Related]
6. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.
Genitsch V; Zlobec I; Thalmann GN; Fleischmann A
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):242-7. PubMed ID: 27165976
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
[TBL] [Abstract][Full Text] [Related]
8. MUC1 oncoprotein is a druggable target in human prostate cancer cells.
Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D
Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552
[TBL] [Abstract][Full Text] [Related]
9. MUC1 expression in plasmacytoma.
Paydaş S; Sahin B; Gönlüşen G; Hazar B; Zorludemir S
Leuk Res; 2001 Mar; 25(3):221-5. PubMed ID: 11226518
[TBL] [Abstract][Full Text] [Related]
10. Effective Prediction of Prostate Cancer Recurrence through the
Gu Y; Lin X; Kapoor A; Li T; Major P; Tang D
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498739
[TBL] [Abstract][Full Text] [Related]
11. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
[TBL] [Abstract][Full Text] [Related]
12. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
13. Activation of AMPKα mediates additive effects of solamargine and metformin on suppressing MUC1 expression in castration-resistant prostate cancer cells.
Xiang S; Zhang Q; Tang Q; Zheng F; Wu J; Yang L; Hann SS
Sci Rep; 2016 Nov; 6():36721. PubMed ID: 27830724
[TBL] [Abstract][Full Text] [Related]
14. IQGAP3 is relevant to prostate cancer: A detailed presentation of potential pathomechanisms.
Mei W; Dong Y; Gu Y; Kapoor A; Lin X; Su Y; Vega Neira S; Tang D
J Adv Res; 2023 Dec; 54():195-210. PubMed ID: 36681115
[TBL] [Abstract][Full Text] [Related]
15. Expression of KL-6/MUC1 in pancreatic cancer tissues and its potential involvement in tumor metastasis.
Xu H; Inagaki Y; Seyama Y; Du G; Wang F; Kokudo N; Tang W
Oncol Rep; 2011 Aug; 26(2):371-6. PubMed ID: 21617869
[TBL] [Abstract][Full Text] [Related]
16. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
17. Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel Towards Prostate Cancer Relapse.
Gu Y; Chow MJ; Kapoor A; Lin X; Mei W; Tang D
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33578925
[TBL] [Abstract][Full Text] [Related]
18. Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients.
Li Q; Li Q; Nuccio J; Liu C; Duan P; Wang R; Jones LW; Chung LW; Zhau HE
Prostate; 2015 Sep; 75(12):1312-21. PubMed ID: 25990623
[TBL] [Abstract][Full Text] [Related]
19. The bone microenvironment invigorates metastatic seeds for further dissemination.
Zhang W; Bado IL; Hu J; Wan YW; Wu L; Wang H; Gao Y; Jeong HH; Xu Z; Hao X; Lege BM; Al-Ouran R; Li L; Li J; Yu L; Singh S; Lo HC; Niu M; Liu J; Jiang W; Li Y; Wong STC; Cheng C; Liu Z; Zhang XH
Cell; 2021 Apr; 184(9):2471-2486.e20. PubMed ID: 33878291
[TBL] [Abstract][Full Text] [Related]
20. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
